ClinicalTrials.gov
ClinicalTrials.gov Menu

Anakinra and Kawasaki Disease (KAWAKINRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02390596
Recruitment Status : Recruiting
First Posted : March 17, 2015
Last Update Posted : September 18, 2018
Sponsor:
Collaborator:
Sobi
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The study is designed to assess the efficacy and safety of anakinra, an interleukin 1 receptor antagonist, in patients with Kawasaki disease who failed to respond to standard treatment:e.g. one infusion of 2g/kg of intravenous immunoglobulins.

Condition or disease Intervention/treatment Phase
Kawasaki Disease Children Drug: Anakinra Phase 2

Detailed Description:

Kawasaki disease (KD), is the most frequent vasculitis in children before 5 years, and the main cause of acquired cardiomyopathy in adulthood. The prognosis of KD is influenced by early recognition and treatment by intravenous immunoglobulins (IVIG), which represent the standard of care and decrease significantly the risk of coronary aneurysms. Despite a first infusion of IVIG, 20% of KD patients remain febrile and are at high risk of coronary vasculitis. To date there is no agreement for a more effective second line treatment. On the basis of the autoinflammatory pattern of KD, we hypothesize that anti IL-1 blocking agents could bring a rapid and sustained effect on systemic and coronary inflammation in patients with KD.

Aim of the study

  • To assess the efficacy of anakinra (IL-1R1receptor antagonist) in patients with KD who fail to respond to one infusion of IVIg (standard treatment).
  • To assess the efficacy of anakinra on disease activity
  • To assess the efficacy of anakinra on coronary lesions (eg: dilatation and aneurysm
  • To assess the safety and tolerability of anakinra Patients and methods A Proof of concept (quasi experimental, non randomized cohort) study. This is a 3-year open-label, prospective multicenter trial of Anakinra in patients with acute KD who failed to respond to a first infusion of IVIG within 48h. Patients will be eligible to enter the study if they have persistence (or recrudescence of fever) within 48 hours after the infusion of IVIg, and if they have given their informed consent to enter the study. After appropriate screening, the study treatment will be initiated between J7 and J14 days of illness to expect full clinical effect. The only primary endpoint will be the absence of fever after 48 h of treatment (assessed at J3 of study treatment, visit 3, before the third injection of anakinra). If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra (4mg/kg) at day 3 instead of 2mg/kg. Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.

Expected results and expected public health benefit Anakinra treatment is expected to reduce the early and long term mortality of patients with KD, by a rapid and sustained effect on vascular inflammation. The safety of anakinra is expected to be good, as the drug has a very short half-life, which allows its rapid withdrawal in case of serious adverse event. The use of anakinra, is not associated with the risk of contamination by infectious agents, which remains even minimal, a possibility with the use of IVIG


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIa Multicenter Trial to Assess the Efficacy, and Safety of Anakinra in Patients With Intravenous Immunoglobulin-resistant Kawasaki Disease
Actual Study Start Date : February 5, 2016
Estimated Primary Completion Date : April 5, 2019
Estimated Study Completion Date : April 5, 2019


Arm Intervention/treatment
Experimental: Anakinra Drug: Anakinra
The dose of Anakinra will be 2mg/kg (patients <10kg and/or <8 months: 4mg/kg). If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra 4mg/kg (patients <10kg and/or <8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients <10kg and/or <8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
Other Name: Kineret




Primary Outcome Measures :
  1. Absence of fever [ Time Frame: within the 48 hours after the treatment by anakinra (after the last escalation dose, if any necessary) ]
    The main efficacy evaluation criterion: the patient must reach a body (axillary, tympanic, oral) temperature <38 within 48 hours of treatment by anakinra (after the last escalation dose, if any necessary)


Secondary Outcome Measures :
  1. Reduction in physician assessment of disease activity, on a 10 points scale, of at least to 50% [ Time Frame: between baseline and day15 ]
  2. Reduction in patient's parents assessment of disease activity, on a 10 points scale, of to at least 50% [ Time Frame: between baseline and day15 ]
  3. Resolution of coronary abnormalities by echocardiogram if present [ Time Frame: at day45 ]
  4. CRP normalization [ Time Frame: between baseline and day15 ]
  5. Adverse events frequency [ Time Frame: between baseline and day45 ]
    Defined with physical exam, injection tolerability, vital signs, TB risk, laboratory evaluations, echocardiogram



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   3 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients, male and female, at any age ≥ 3 months (5 kg) of life, with KD according to the American Heart Association definition for complete or incomplete KD. fever ≥ 5 days and ≥ 4 of 5 main clinical signs: modification of the extremities, polymorphic exanthema, bilateral bulbar not exudative conjunctivitis, erythema of the lips or oral cavity, and cervical lymph nodes usually unilateral > 1.5 cm in diameter. In the presence of less than 4 clinical criteria and 5 days of fever, the diagnosis of disease KD is proposed in case of coronary abnormalities (at least one dilated coronary artery with internal diameter ≥ 2,5 SD from the mean normalized for body surface area (Z score) as determined by echocardiography. For indicative purpose, in case of incomplete KD, other biological supportive criteria for incomplete KD can help to ensure the diagnosis: leucocytosis, elevated CRP, elevated ESR, anaemia, hyponatremia, elevated ASAT, ALAT and gGT, hyperlipidaemia.
  • Patients who failed to respond to standard therapy of KD:, e.g. Persistence or recrudescence of fever ≥ 38°C, 48 hours after the infusion of 2g/kg of IV Ig,
  • Weight ≥5Kg
  • Patient, parent or legal guardian's written informed consent is required
  • Patient with health insurance
  • Patient agrees to have effective contraception for the duration of participation in the research

Exclusion Criteria:

  • Preterm and neonates, pregnancy
  • Patients suspected with another diagnosis
  • Patients with overt concomitant bacterial infection
  • Patients previously treated with another biotherapy
  • Patients with any type of immunodeficiency or cancer
  • Patients with increased risk of TB infection
  • Recent tuberculosis infection or with active TB

    • Close contact with a patient with TB
    • Patients recently arrived less than 3 months from a country with high prevalence of TB
    • A chest radiograph suggestive of TB
  • Patients with end stage renal disease: NKF stages ≥4; eGFR≤29mL/min/1.73 m2 or diabetes mellitus or neutropenia <1500/mm3 or liver failure
  • Hypersensitivity to the active substance or to any of the excipients (citric acid and anhydrous; sodium chloride disodium edetate dehydrate polysorbate 80; sodium hydroxide; water for injections)
  • Patient already included in a biomedical research other than observational (e.g.; cohort, registry)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02390596


Contacts
Contact: Isabelle Koné-Paut, MD, PhD +33 (0)1 45 21 32 46 isabelle.kone-paut@bct.aphp.fr

Locations
France
AP-HP,Bicêtre Hospital Recruiting
Le Kremlin-Bicêtre, France, 94275
Contact: Isabelle Koné-Paut, MD, PhD    +33 (0)1 45 21 32 46    isabelle.kone-Paut@bct.aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Sobi
Investigators
Principal Investigator: Isabelle Koné-Paut, MD, PhD AP-HP, Bicêtre Hospital

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02390596     History of Changes
Other Study ID Numbers: AOM13520
2014-002715-41 ( EudraCT Number )
First Posted: March 17, 2015    Key Record Dates
Last Update Posted: September 18, 2018
Last Verified: September 2018

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Kawasaki disease
anti Interleukin 1 treatment
anakinra
resistance to IVIg
coronary aneurysms
phase II trial

Additional relevant MeSH terms:
Mucocutaneous Lymph Node Syndrome
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Lymphatic Diseases
Skin Diseases, Vascular
Skin Diseases
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents